Your shopping cart is currently empty

NCT-505 is a potent and selective inhibitor of aldehyde dehydrogenase (ALDH1A1, IC50 = 7 nM) and a weak inhibitor of hALDH1A2, hALDH1A3, hALDH2, hALDH3A1 with IC50 values of >57 μM, 22.8 μM, 20.1 μM, and >57 μM, respectively.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $117 | In Stock | In Stock | |
| 5 mg | $248 | In Stock | In Stock | |
| 10 mg | $371 | In Stock | In Stock | |
| 25 mg | $591 | In Stock | In Stock | |
| 50 mg | $798 | In Stock | In Stock | |
| 100 mg | $1,070 | In Stock | In Stock | |
| 200 mg | $1,430 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $285 | In Stock | In Stock |
| Description | NCT-505 is a potent and selective inhibitor of aldehyde dehydrogenase (ALDH1A1, IC50 = 7 nM) and a weak inhibitor of hALDH1A2, hALDH1A3, hALDH2, hALDH3A1 with IC50 values of >57 μM, 22.8 μM, 20.1 μM, and >57 μM, respectively. |
| Targets&IC50 | ALDH2 (human):20.1 μM , ALDH1A1:7 nM , ALDH1A3 (human):22.8 μM , ALDH1A2 (human):>57 μM , ALDH3A1 (human):>57 μM |
| In vitro | NCT-505 (compound 86) is a potent and selective aldehyde dehydrogenase (ALDH1A1) inhibitor with IC50 of 7 nM, weakly inhibits hALDH1A2, hALDH1A3, hALDH2, hALDH3A1 (IC50s, >57, 22.8, 20.1, >57 μM ). NCT-505 has no significant inhibitory effect on 5-hydroxyprostaglandin dehydrogenase (HPGD) and type 4 hydroxysteroid dehydrogenase (HSD17β4) (IC50, >57 μM). In addition, NCT-505 showed potent cellular viability, reducing the viability of OV-90 cells with EC50 of 2.10-3.92 μM. NCT-505 is also cytotoxic to SKOV-3-TR cells with IC50 of 1, 3, 10, 20, 30 μM in titration analysis[1]. |
| Molecular Weight | 521.61 |
| Formula | C27H28FN5O3S |
| Cas No. | 2231079-74-4 |
| Smiles | CS(=O)(=O)N1CCN(CC1)C(=O)c1cnc2ccc(F)cc2c1N1CCC(CC1)(C#N)c1ccccc1 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (105.44 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.83 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.